Cargando…

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?

Detalles Bibliográficos
Autores principales:	Wongariyapak, Amarin, Roulstone, Victoria, Melcher, Alan A., Pedersen, Malin, Harrington, Kevin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477632/ https://www.ncbi.nlm.nih.gov/pubmed/37675296 http://dx.doi.org/10.21037/atm-2023-5

Ejemplares similares

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
por: Ascierto, Paolo A., et al.
Publicado: (2017)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021)

The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism
por: McLaughlin, Martin, et al.
Publicado: (2020)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

What goes in the regulatory clinical pharmacology package for an oncolytic virus?
por: Yum, Sun Young, et al.
Publicado: (2023)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
por: Flaherty, Katie R, et al.
Publicado: (2023)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
por: Lovatt, Charlotte, et al.
Publicado: (2023)

Oncolytic Virus Immunotherapy
por: Marchini, Antonio, et al.
Publicado: (2021)

Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma
por: Vijayakumar, Gayathri, et al.
Publicado: (2019)

Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
por: Xie, Daoyuan, et al.
Publicado: (2023)

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
por: Tang, Tianyu, et al.
Publicado: (2022)

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
por: Thomas, Suzanne, et al.
Publicado: (2019)

Oncolytic immunotherapy for metastatic cancer: lessons and future strategies
por: Guo, Zong-Sheng
Publicado: (2020)

Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma
por: Kuryk, Lukasz, et al.
Publicado: (2019)

Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
por: Khushalani, Nikhil I., et al.
Publicado: (2023)

Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
por: LaRocca, Christopher J., et al.
Publicado: (2018)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer
por: Mansfield, D C, et al.
Publicado: (2016)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
por: Hwang, June Kyu, et al.
Publicado: (2020)

Two roads for oncolytic immunotherapy development
por: Kaufman, Howard L., et al.
Publicado: (2019)

Oncolytic viruses in melanoma
por: Robinson, Camille, et al.
Publicado: (2022)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Oncolytic virotherapy targeting the IL15 pathway
por: Yoo, So Young, et al.
Publicado: (2023)

PTEN potentiation of oncolytic HSV therapy for glioblastoma
por: Migliarese, Christian, et al.
Publicado: (2023)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
por: Haanen, John, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8ptbdfjqh92pg3uqp5v2tpm7b1